|
|
|
| Correlation between Changes of Serum GDF-15, Lp-PLA2 and Cardiac Function and Ventricular Remodeling in Patients with CHF |
| GE Zhen-zhong, GONG Zhao-wei, NING Yi, et al |
| Wuxi People's Hospital, Wuxi, Jiangsu 214000 |
|
|
|
|
Abstract 【Objective】 To investigate the relationship between the changes of serum growth differentiation factor-15 (GDF-15) and lipoprotein associated phospholipase A2 (Lp-PLA2) and cardiac function and ventricular remodeling in patients with chronic heart failure (CHF). 【Methods】 A total of 140 patients with CHF Treated in Wuxi People's Hospital from January 2017 to March 2019 (observation group) and 70 healthy volunteers in the same period (control group). The levels of serum GDF-15, Lp-PLA2, N-terminal pro brain natriuretic peptide (NT-proBNP) and cardiac function indexes [left ventricular ejection fraction (LVEF%), left ventricular short axis shortening (FS%) and left ventricular mass index (LVMI)] were compared between the two groups, and their correlation was analyzed.【Results】The levels of serum GDF-15, Lp-PLA2 and NT-proBNP in the observation group were significantly higher than those in the control group (P<0.05). The level of LVMI in the observation group was significantly higher than that in the control group, and the levels of LVEF and FS were significantly lower than that in the control group (P<0.05). The levels of serum GDF-15 and Lp-PLA2 in CHF patients with NYHA grade Ⅱ, Ⅲ and Ⅳ increased gradually, and there were significant differences between the groups (mean P<0.05). The levels of serum GDF-15 and Lp-PLA2 in CHF were significantly negatively correlated with LVEF and FS (P<0.05), and positively correlated with LVMI and serum NT-proBNP (P<0.05). 【Conclusion】 The levels of serum GDF-15 and Lp-PLA2 in patients with CHF are significantly increased, which are closely related to cardiac function and ventricular remodeling.
|
|
Received: 08 July 2019
|
|
|
|
|
|
[1] LIU C, GENG J, YE X, et al. Change in lipid profile and risk of new-onset atrial fibrillation in patients with chronic heart failure[J].Medicine,2018,97(39):485-487.
[2] 顾红莲. 慢性心力衰竭患者心脏标志物水平及超声心动图特点[J].中华心脏与心律电子杂志, 2018, 6(4):17-21.
[3] 王雅萍.心力衰竭患者脂蛋白磷脂酶A2与B型利钠肽相关性研究[J].南通大学学报(医学版),2018,38(1):15-17.
[4] 王喆. 《中国心力衰竭诊断和治疗指南2014》解读[J].中国临床医生杂志,2016,44(5):14-16.
[5] GRANGER B B, EKMAN I, HERNANDEZ A F, et al. Results of the Chronic Heart Failure Intervention to Improve MEdication Adherence study: A randomized intervention in high-risk patients[J].Am Heart J,2015,169(4):539-548.
[6] 宋醒良.应用操作特征曲线分析生物学标志物在慢性心力衰竭中的价值[J].当代医学, 2019, 25 (7):11-14.
[7] 吕冬,许锦荣,陈玲,等. sST2、脂联素、生长分化因子-15联合检测对老年心力衰竭的诊断意义[J].广东医科大学学报,2018,36(4):397-399.
[8] 章蓓蓓.脂蛋白磷脂酶A2与慢性心力衰竭患者预后的关系[J].中国心血管病研究,2017,15(4):332-335.
[9] 王洪静.心力衰竭患者血清脂蛋白相关磷脂酶A2和B型尿钠肽的表达[J].中国老年学杂志,2017,37(4):847-848.
[10] 马少雯,殷华,梁时钱,等. 生长分化因子-15及脑钠肽前体对慢性心力衰竭患者左室重构的预测价值[J].中国现代医药杂志,2018,20(8):35-37.
[11] 徐亮,陈燕春,殷云杰,等. 血清Lp-PLA2在心房颤动并心力衰竭患者体内的表达及其临床价值[J].重庆医学,2019,48(6):980-982.
[12] 关敬树,周云,缪志静,等. 慢性心力衰竭急性加重患者血清生长分化因子-15水平及其对预后的评估意义[J].中国医师杂志,2016,18(5):680-683. |
|
|
|
2021, Vol. 38 
